BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GlycoMimetics\, Inc. (renamed Crescent Biopharma\, Inc.\, June
  2025) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies GlycoMimetics\, Inc. (renamed Cre
 scent Biopharma\, Inc.\, June 2025)'s drugs run\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07335497-10868@assetmemo.bio
DTSTAMP:20261121T011245Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:CR-001: Phase 1/2 readout est. (NCT07335497)
DESCRIPTION:CR-001\, phase 1/2\, Solid Tumors.\nStudy: CR-001 in Adult Part
 icipants With Locally Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: February 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cr-001#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07335497
URL:https://assetmemo.bio/drug/cr-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
